Mesenchymal stem cells (MSCs) are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, and adipocytes. MSCs show promise for a number of therapeutic applications such as regenerative medicine, wound healing, anti-fibrosis and immune modulation. They are relatively easy to isolate and expand in culture which makes them attractive for clinical applications and research.
Key Takeaways
Key players operating in the Mesenchymal Stem Cells market are Pluristem Therapeutics, LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis, Celprogen, Cell Applications, PromoCell GmbH, Cyagen Biosciences, Human Longevity Inc., Axol Bioscience, Cytori Therapeutics, Eutilex Co.Ltd., ID Pharma Co. Ltd., BrainStrom Cell Therapeutics, Cytori Therapeutics Inc., Neovii Biotech, Angel Biotechnology, California Stem Cell Inc., Stemcelltechnologies Inc., and Celgene Corporation Inc.
The rising Mesenchymal Stem Cells Market Demand is driven by a growing number of clinical trials exploring new MSC therapeutic applications. Over the past decade, phase I, II, and III trials have evaluated MSC therapy for conditions like graft-versus-host disease, Crohn’s disease, and heart disease. However, further evidence-based trials are needed to validate MSCs’ therapeutic benefits.
Technological advancements are also fueling the growth of mesenchymal stem cells market. Companies are developing novel techniques like microencapsulation that help overcome challenges like low viability and engraftment of MSCs after transplantation. 3D bioprinting is another emerging technology that facilitates precise spatial organization of stem cells and growth factors to fabricate tissues and organs. This helps optimize the regenerative potential of stem cell therapy.
Market Trends
A key trend in the mesenchymal stem cells market is the increasing focus on development of off-the-shelf allogenic MSC therapy. While traditional autologous MSC transplantation requires harvesting and culturing of a patient’s own stem cells, allogenic therapy uses commercially available “universal donor” MSCs that can be administered directly to patients without prior culturing. This makes treatment much more timely and cost-effective. Another trend is recruitment of MSCs as delivery vehicles for targeted delivery of drugs, gene therapies and imaging probes. Researchers are exploring application of stem cell-based therapies for a wide range of medical conditions.
Market Opportunities
Promising opportunities exist in joint repair/regeneration and cartilage regeneration applications of MSCs. Preclinical research demonstrates the chondroprotective and regenerative potential of MSCs in repair of cartilage and bone defects caused by osteoarthritis and other joint injuries. The rising global prevalence of osteoarthritis driven by aging population points towards a huge clinical need for effective treatments. Development of techniques to optimize homing, survival and regenerative functions of transplanted MSCs also offers opportunities to maximize clinical benefits. Expanding the pipeline of clinical applications by leveraging latest stem cell biology and tissue engineering approaches will further spur market growth.
Impact of COVID-19 in Mesenchymal Stem Cells Market
The COVID-19 pandemic has significantly impacted the growth of the mesenchymal stem cells market. During the initial stages of the outbreak, as various countries imposed strict lockdowns, there was disruption in the supply chain and logistical challenges. This hampered clinical research activities involving mesenchymal stem cells. However, as COVID-19 affects the respiratory system, interest in mesenchymal stem cell therapy grew substantially owing to their anti-inflammatory and immunomodulatory properties. Several clinical trials were launched during 2020-21 to evaluate the safety and efficacy of mesenchymal stem cells in treating COVID-19 patients. With positive preliminary results, investment in MSC based research for COVID-19 is increasing. It is expected that in the post COVID era, the market will witness robust growth driven by its potential therapeutic applications for lung injuries caused due to coronavirus.
Geographically, North America currently dominates the mesenchymal stem cells market in terms of value, given the large investments in regenerative medicine research in the US. However, Asia Pacific is projected to be the fastest growing regional market during the forecast period. This is attributed to factors such as rising geriatric population, increasing healthcare expenditure, and growing stem cell banking facilities in countries like China, India and Japan. Presence of leading pharmaceutical companies and biotech firms in these nations would further aid in market expansion.
Geographically, North America currently dominates the mesenchymal stem cells market in terms of value, given the large investments in regenerative medicine research in the US. However, Asia Pacific is projected to be the fastest growing regional market during the forecast period. This is attributed to factors such as rising geriatric population, increasing healthcare expenditure, and growing stem cell banking facilities in countries like China, India and Japan. Presence of leading pharmaceutical companies and biotech firms in these nations would further aid in market expansion.
Get More Insights – Mesenchymal Stem Cells Market
Get This Report in Japanese Language –間葉系幹細胞市場
Get This Report in Korean Language –중간엽줄기세포 시장
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)